Diluted brimonidine for improving early postoperative symptoms and subconjunctival hemorrhage after PRK and LASIK.

IF 1 4区 医学 Q3 OPHTHALMOLOGY
Arquivos brasileiros de oftalmologia Pub Date : 2026-07-10 eCollection Date: 2026-01-01 DOI:10.5935/0004-2749.2025-0330
Natália Fernandes Gonçalves Napolitano, Ana Vega Carreiro de Freitas, Luís Gustavo de Imparato Rodrigues Ribeiro, Daniella Villas Boas Fairbanks, Fernando Antonio Galhardo Tarcha, Vagner Loduca Lima, Bernardo Kaplan Moscovici, Edmundo José Velasco Martinelli
{"title":"Diluted brimonidine for improving early postoperative symptoms and subconjunctival hemorrhage after PRK and LASIK.","authors":"Natália Fernandes Gonçalves Napolitano, Ana Vega Carreiro de Freitas, Luís Gustavo de Imparato Rodrigues Ribeiro, Daniella Villas Boas Fairbanks, Fernando Antonio Galhardo Tarcha, Vagner Loduca Lima, Bernardo Kaplan Moscovici, Edmundo José Velasco Martinelli","doi":"10.5935/0004-2749.2025-0330","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess whether low-concentration brimonidine (0.025%) improves early postoperative signs and symptoms following femtosecond laser-assisted in situ keratomileusis and photorefractive keratectomy without affecting pupil diameter or flap safety.</p><p><strong>Methods: </strong>This prospective, randomized, double-masked, contralateral-eye, single-center study was conducted between January and September 2024. In each patient, one eye received 0.025% brimonidine 15-30 min before surgery (mean: 21.3 ± 2.4 min), whereas the fellow eye received 0.15% sodium hyaluronate (control). Primary outcomes on postoperative Day 1 included subconjunctival hemorrhage laser-assisted in situ keratomileusis and patient-reported symptoms (0-10 scale; composite score). Pupil diameter was measured pre-ablation. Statistical analyses included McNemar and paired t tests, with a significant threshold of α=0.05.</p><p><strong>Results: </strong>A total of 124 patients were included (54 laser-assisted in situ keratomileusis and 70 photorefractive keratectomy). Pupil diameter did not differ significantly between brimonidine-treated and control eyes (laser-assisted in situ keratomileusis: 2.63 ± 0.47 vs. 2.69 ± 0.42 mm, p=0.273; photorefractive keratectomy: 2.56 ± 0.44 vs. 2.61 ± 0.39 mm, p=0.116). In laser-assisted in situ keratomileusis, subconjunctival hemorrhage occurred less frequently in brimonidine-treated eyes both intraoperatively (9.3% vs. 46.3%, p<0.001) and on postoperative Day 1 (9.3% vs. 50.0%, p<0.001). Composite symptom scores were significantly lower in brimonidine-treated eyes in both laser-assisted in situ keratomileusis and photorefractive keratectomy groups (p=0.001 for both).</p><p><strong>Conclusions: </strong>Preoperative administration of low-concentration brimonidine (0.025%) significantly reduced subconjunctival hemorrhage in laser-assisted in situ keratomileusis without comprising flap integrity. It also improved early postoperative symptoms in laser-assisted in situ keratomileusis and photorefractive keratectomy, without affecting pupil diameter. These findings support the use of dilute brimonidine as a safe and effective adjunct to enhance the immediate postoperative experience in refractive surgery.</p>","PeriodicalId":8397,"journal":{"name":"Arquivos brasileiros de oftalmologia","volume":"89 3","pages":"e20250330"},"PeriodicalIF":1.0000,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de oftalmologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5935/0004-2749.2025-0330","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To assess whether low-concentration brimonidine (0.025%) improves early postoperative signs and symptoms following femtosecond laser-assisted in situ keratomileusis and photorefractive keratectomy without affecting pupil diameter or flap safety.

Methods: This prospective, randomized, double-masked, contralateral-eye, single-center study was conducted between January and September 2024. In each patient, one eye received 0.025% brimonidine 15-30 min before surgery (mean: 21.3 ± 2.4 min), whereas the fellow eye received 0.15% sodium hyaluronate (control). Primary outcomes on postoperative Day 1 included subconjunctival hemorrhage laser-assisted in situ keratomileusis and patient-reported symptoms (0-10 scale; composite score). Pupil diameter was measured pre-ablation. Statistical analyses included McNemar and paired t tests, with a significant threshold of α=0.05.

Results: A total of 124 patients were included (54 laser-assisted in situ keratomileusis and 70 photorefractive keratectomy). Pupil diameter did not differ significantly between brimonidine-treated and control eyes (laser-assisted in situ keratomileusis: 2.63 ± 0.47 vs. 2.69 ± 0.42 mm, p=0.273; photorefractive keratectomy: 2.56 ± 0.44 vs. 2.61 ± 0.39 mm, p=0.116). In laser-assisted in situ keratomileusis, subconjunctival hemorrhage occurred less frequently in brimonidine-treated eyes both intraoperatively (9.3% vs. 46.3%, p<0.001) and on postoperative Day 1 (9.3% vs. 50.0%, p<0.001). Composite symptom scores were significantly lower in brimonidine-treated eyes in both laser-assisted in situ keratomileusis and photorefractive keratectomy groups (p=0.001 for both).

Conclusions: Preoperative administration of low-concentration brimonidine (0.025%) significantly reduced subconjunctival hemorrhage in laser-assisted in situ keratomileusis without comprising flap integrity. It also improved early postoperative symptoms in laser-assisted in situ keratomileusis and photorefractive keratectomy, without affecting pupil diameter. These findings support the use of dilute brimonidine as a safe and effective adjunct to enhance the immediate postoperative experience in refractive surgery.

稀释溴莫尼定改善PRK和LASIK术后早期症状和结膜下出血。
目的:评价低浓度溴莫尼定(0.025%)是否能改善飞秒激光辅助原位角膜磨除术和光屈光性角膜切除术术后早期体征和症状,同时不影响瞳孔直径和皮瓣的安全性。方法:这项前瞻性、随机、双盲、双侧眼、单中心研究于2024年1月至9月进行。每例患者在手术前15-30分钟(平均21.3±2.4分钟),一只眼接受0.025%溴莫尼定治疗,另一只眼接受0.15%透明质酸钠治疗(对照组)。术后第1天的主要结果包括结膜下出血激光辅助原位角膜磨砂术和患者报告的症状(0-10分;综合评分)。消融前测量瞳孔直径。统计学分析采用McNemar检验和配对t检验,显著性阈值为α=0.05。结果:共纳入124例患者,其中激光辅助原位角膜磨除术54例,光屈光性角膜切除术70例。布莫那定治疗组和对照组的瞳孔直径无显著差异(激光辅助原位角膜磨除术:2.63±0.47 vs 2.69±0.42 mm, p=0.273;光屈光性角膜切除术:2.56±0.44 vs 2.61±0.39 mm, p=0.116)。在激光辅助原位角膜磨除术中,使用溴莫尼定治疗的眼的结膜下出血发生率较低(9.3% vs. 46.3%)。结论:术前给予低浓度溴莫尼定(0.025%)可显著减少不破坏皮瓣完整性的激光辅助原位角膜磨除术的结膜下出血。它还改善了激光辅助原位角膜磨砂术和光屈光性角膜切除术术后早期症状,而不影响瞳孔直径。这些发现支持使用稀溴硝定作为一种安全有效的辅助手段来增强屈光手术术后的即时体验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
200
审稿时长
6-12 weeks
期刊介绍: The ABO-ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - electronic version), the official bimonthly publication of the Brazilian Council of Ophthalmology (CBO), aims to disseminate scientific studies in Ophthalmology, Visual Science and Health public, by promoting research, improvement and updating of professionals related to the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书